Does JCV Antibody Positivity Encourage Cessation of Natalizumab Therapy in Multiple Sclerosis?

Lonergan, Roisin; Kinsella, Katie; Kelly, Siobhán; Duggan, Marguerite; Scott, Jacqueline; O’Rourke, Killian; Lynch, Timothy; Hutchinson, Michael; Tubridy, Niall; McGuigan, Christopher

doi:10.1136/jnnp-2013-306573.181

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PML risk appeared to influence treatment discontinuation, particularly for those at highest risk, 34 although there was also conflicting evidence. 35 A multicentre prospective study in Italy followed patients who had received natalizumab for at least 2 years without worsening disability. 37 Patients who discontinued natalizumab due to AEs and those with baseline EDSS ≥6 were excluded.…”

Section: Infusion Therapies (Four Studies)mentioning

confidence: 99%

Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies

Harty¹,

Wong²,

Tang³

et al. 2019

European Neurological Review

View full text Add to dashboard Cite

Section: Infusion Therapies (Four Studies)mentioning

confidence: 99%

Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies

Harty¹,

Wong²,

Tang³

et al. 2019

European Neurological Review

View full text Add to dashboard Cite

Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy

Borchardt

Berger

2016

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis

Schwab

Schneider‐Hohendorf

Wiendl

2014

International Immunology

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a disorder of putative autoimmune origin, where immune cells invade the central nervous system and cause damage by attacking the myelin sheath of nerve cells. The blockade of the integrin very late antigen-4 (VLA-4) with the monoclonal antibody natalizumab has become the most effective therapy against MS since its approval in 2004. It is assumed that the inhibition of VLA-4-mediated immune cell adhesion to the endothelium of the blood-brain barrier (BBB) alleviates pathogenic processes of MS and, therefore, reduces disease severity and burden. Not all approaches to treat additional immune-mediated disorders (e.g. Rasmussen encephalitis and neuromyelitis optica) with natalizumab have been successful, but allowed researchers to gain additional insight into mechanisms of specific immune cell subsets' migration through the BBB in the human system. While the long-term efficacy and general tolerability of natalizumab in MS are clear, the over 400 cases of natalizumab-associated progressive multifocal leukoencephalopathy (PML) have been of great concern and methods of risk stratification in patients have become a major area of research. Modern risk stratification includes established factors such as treatment duration, previous immune-suppressive therapy, and anti-John Cunningham virus (JCV) antibody seropositivity, but also experimental factors such as anti-JCV antibody titers and levels of L-selectin. Today, anti-VLA-4 therapy is reserved for patients with highly active relapsing-remitting MS and patients are monitored closely for early signs of potential PML.

show abstract

Does JCV Antibody Positivity Encourage Cessation of Natalizumab Therapy in Multiple Sclerosis?

Cited by 3 publications

References 0 publications

Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies

Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies

Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis

Contact Info

Product

Resources

About